Longreach I echo Collie's sentiments.
You asked about other contributions on the EBR HC posts.
I attended the Sydney briefing a ew weeks ago and it confirmed to me that the product has a great future.
I am not sufficiently medically qualified (technically) to post on the products. What it showed was the great potential. It may /will take some time to get to US FDA approval and then adoption by the conservative medical profession, but I do think the benefits will be realised.
The cost of constant treatments and monitoring of old generation devices will drive the adoption of EBR's product.
Thanks for your very thorough researched posts.
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
0.030(2.44%) |
Mkt cap ! $565.8M | |||
| Open | High | Low | Value | Volume |
| $1.21 | $1.27 | $1.21 | $804.3K | 643.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3624 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 3694 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| EBR (ASX) Chart |